ABMD News and Press, ABIOMED Inc. From 09/13/22

Abiomed (Nasdaq: ABMD) will highlight how Impella heart pumps help heart teams achieve more complete high-risk revascularization and heart recovery in the catheterization lab and operating room at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference , held in Bost...

Summary Generation Investment Management’s 13F portfolio value decreased from $21.84B to $18.35B this quarter. They added Mastercard and increased Amazon.com, Microsoft, Trane Technologies, and Analog Devices while reducing Baxter International, Becton Dickinson, and Alphab...

Consistent evidence supports benefits of complete revascularization on LVEF, heart failure symptoms Abiomed (Nasdaq: ABMD) announces the results of the Restore EF study demonstrate Impella-supported high-risk percutaneous coronary intervention (PCI) leads to signific...

Baillie Gifford’s 13F portfolio value decreased from ~$143B to ~$97.51B this quarter. They increased Spotify and Royalty Pharma while decreasing Cloudflare, Petrobras, BeiGene, CBRE Group, Teladoc, and Peloton Interactive. The top three positions are Moderna, Tesla Motors, ...

Abiomed (NASDAQ: ABMD) , a maker of medical devices that provide circulatory support, including the Impella heart pumps used in cardiac surgery, saw its shares climb 18.4% in July, according to data from S&P Global Intelligence . Abiomed's shares closed at $247.51 on June 30...

Abiomed, Inc. (ABMD) Q1 2023 Results Conference Call August 4, 2022 08:00 AM ET Company Participants Nicole Nath - Manager, Investor Relations Mike Minogue - President and Chief Executive Officer Todd Trapp - Vice President and Chief Financial Officer Confe...

Abiomed ( NASDAQ: ABMD ) is down 4% in Thursday afternoon trading after the medical technology company lowered its full-year revenue guidance due to impacts from foreign exchange rates. At its low today, the heart pump maker was down ~7% , the biggest intraday...

Abiomed came in with another set of robust earnings yesterday, with double-digit growth from top to bottom. Earnings remain steady, however, the company exhibits the profitability features investors are paying a premium for. Valuations are supporting, and we look to be paying a ~3...

Abiomed press release ( NASDAQ: ABMD ): Q1 Non-GAAP EPS of $1.25 beats by $0.19 . Revenue of $277M (+9.7% Y/Y) beats by $0.54M . Worldwide product revenue of $264 million, an increase of 10% U.S. product revenue of $216 million, an increase of 9%. ...

ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended June 30, 2022. First Quarter 2023 Financial Highlights: Revenue of $277 million, an increase of 10%, or 12% in consta...